Drugs / SkQ1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT02121301 | Apr → Jun 2014 | dry eye syndrome | Mitotech, SA | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 3 | NCT04206020 Comparator | Dec 2019 → Oct 2020 | dry eye syndrome | Mitotech, SA | Completed | No outcome recorded |
| Phase 3 | NCT03764735 Comparator | Dec 2018 → Feb 2019 | dry eye syndrome | Mitotech, SA | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 13
| Date | Issuer | Release |
|---|---|---|
| 2025-06-06 | Mitotech, SA | Results Mitotech to present at Obesity Science and Innovation 2025 mitotechpharma.com ↗
Our latest findings in large non-rodent animal models show that once-daily oral treatment with SkQ1 can reduce body weight by up to 27%, |
| 2024-11-15 | Mitotech, SA | Results Mitotech Presents New positive Animal Efficacy Data for SkQ1 in MASH Treatment at The 75th Liver Meeting mitotechpharma.com ↗
Mitotech Ltd., a clinical-stage biotechnology company focused on developing mitochondria-based therapies, today announced the presentation of compelling new animal efficacy data on its investigational compound, SkQ1, a mitochondria-targeted ferroptosis inhibitor, for the treatment of Metabolic Dysfunction-Associated Steatohepatitis ( MASH) at The 75th Liver Meeting® in San Diego, CA. |
| 2024-11-06 | Mitotech, SA | Results Mitotech Unveils Promising New Obesity Treatment Data on SkQ1 at ObesityWeek 2024 mitotechpharma.com ↗
Recent preclinical studies presented at the conference demonstrated SkQ1's potential to improve metabolic function and reduce fat accumulation, while preserving muscle mass in obesity models. |
| 2024-09-17 | Mitotech, SA | Results Mitotech Presents Promising Results in Friedreich’s Ataxia mitotechpharma.com ↗
Those new data demonstrated high level of efficacy of the company’s lead compound SkQ1 – a mitochondria-targeted ferroptosis inhibitor – against ferroptosis and oxidative stress at strikingly low doses. |
| 2021-02-26 | Mitotech, SA | Results Mitotech and Essex Bio-Technology announce positive results of VISTA-2 Phase 3 clinical study in Dry Eye Disease mitotechpharma.com ↗ |
| 2017-10-24 | Mitotech, SA | Results Mitotech announces new Dry Eye data set supporting SkQ1's novel mechanism of action mitotechpharma.com ↗
Mitotech S.A., a Luxembourg-based biotechnology company marketing its Dry Eye drug Visomitin® in Russia, announced positive data from their recent study involving a novel Dry Eye model. |
| 2017-04-26 | Mitotech, SA | Results Mitotech's SkQ1 improved visual acuity in Leber's Hereditary Optic Neuropathy (LHON) patients mitotechpharma.com ↗
Mitotech S.A., a Luxembourg-based clinical stage biotechnology company, announced positive results of a clinical study in Leber's Hereditary Optic Neuropathy (LHON) patients. |
| 2017-03-21 | Mitotech, SA | Results Mitotech's lead compound significantly increased lifespan of rapidly aging mice mitotechpharma.com ↗
Mitotech S.A., a Luxembourg-based clinical stage biotechnology company focused on age-related disorders, highlighted a study by an international group of scientists where Mitotech's lead compound SkQ1 increased longevity of mtDNA mutator mice that are known to exhibit features of premature aging. |
| 2016-09-09 | Mitotech, SA | Regulatory Mitotech S.A. is granted a patent in anti-aging mitotechpharma.com ↗
Mitotech S.A., a Luxembourg-based clinical stage biotechnology company focused on age-related disorders, announced that it received a U.S. patent covering deceleration of aging in living organisms by its lead compound SkQ1. |
| 2016-01-10 | Mitotech, SA | Results Results of SkQ1 U.S. Phase 2 Clinical Study in Patients with Dry Eye Syndrome published in Advances in Therapy journal mitotechpharma.com ↗
Mitotech published the results of SkQ1 Ophthalmic Solution Phase 2 Safety and Efficacy Clinical Study in the Environment and During Challenge in the Controlled Adverse Environment Model in Patients with Dry Eye Syndrome in Advances in Therapy journal. |
| 2015-04-23 | Mitotech, SA | Results Mitotech Announces Phase 2 Data Showing Positive Effect of SkQ1 in Patients with Dry Eye Syndrome mitotechpharma.com ↗
We achieved statistically significant treatment effects in both signs and symptoms of dry eye syndrome. |
| 2013-05-14 | Mitotech, SA | Results Mitotech completes series of uveitis studies mitotechpharma.com ↗
It demonstrated the positive effect of Mitotech's drug SkQ1 on both signs and symptoms of dry eye and the poster will highlight some of the key findings. |
| 2012-12-09 | Mitotech, SA | Results Mitotech's posters at ARVO 2015 in Denver, May 3-7 mitotechpharma.com ↗
Dose response in corneal fluorescein staining measure in mice is a strong indication that SkQ1 will be a promising candidate for treating dry eye syndrome. |
All press releases naming this drug 22 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SkQ1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03764735 ↗ |
| Modality | Other / unclassified | “the novel antioxidative, renewable compound SkQ1” PMID 26733410 ↗ Jan 2016 |
| Route | Topical | “for topical treatment of dry eye signs and symptoms” PMID 26733410 ↗ Jan 2016 |